Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to ...

More information: An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

TG Therapeutics, Inc.’s TGTX share price has dipped by 12.53%, which has investors questioning if this is right time to buy.

a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics ...

In the BLI affinity assay, the affinity levels of these antibodies were equivalent to those of a control antibody, reaching nanomolar or sub-nanomolar levels. In the cell-binding assay ...

Peluntamig is Phanes' first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47. It was granted two orphan drug designations by the FDA for the treatment of SCLC and NEC ...